Skip to Main Content

ANGIO-A: Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumors

About this study

This study looks for effective treatments for childhood solid tumors that have returned after treatment or have never responded to therapy.

Some of these tumors may respond to a type of therapy called immunotherapy. This therapy helps the patient’s immune system see the tumor better and kill it. Disorganized blood vessels make it harder for immunotherapy to work. Immunotherapy may work better if we give medicines to change the blood vessels.

Atezolizumab is a form of immunotherapy. It is active in multiple cancer types. We already know that low-dose cyclophosphamide, bevacizumab, and sorafenib are safe. These medicines effectively target the blood vessels. We want to see how combining those 3 drugs with atezolizumab can help patients.

Eligibility overview

Part 1

  • 1–30 years old
  • Diagnosis of a solid tumor that has grown or has come back after treatment
  • Ability to biopsy the tumor

Part 2

  • 1–30 years old
  • Diagnosis of:
    • Hepatocellular carcinoma that has grown or has come back after treatment
    • Fibrolamellar hepatocellular carcinoma
    • Desmoplastic small round cell tumor
    • A malignant rhabdoid tumor that is not in the central nervous system
    • Ability to biopsy the tumor

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.


Full title:

Safety and Tolerability of Oral Cyclophosphamide and Sorafenib with Intravenous Bevacizumab with the Addition of Atezolizumab in Pediatric Solid Tumor Patients

Study goal:

In Part 1 of this study, we will see if sorafenib, cyclophosphamide, bevacizumab, and atezolizumab can be given safely together without causing serious side effects. Part 2 of the study will find out how well these medicines work in hepatocellular carcinoma, fibrolamellar carcinoma, desmoplastic small round cell tumors, and malignant rhabdoid tumors.


Solid tumors, hepatocellular carcinoma, fibrolamellar hepatocellular carcinoma, sarcomas, malignant rhabdoid tumors, desmoplastic small round cell tumors


1-30 years old

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.


Learn more